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There has been considerable progress during the past
decade in the treatment of patients with acute leukemia,
with many of them achieving complete remission and
long-term survival. Nonetheless, invasive fungal infections
have become a serious problem that cause morbidity
and mortality and may hinder further treatment [1–4].
Although the incidence of fungal infection varies among
studies [5–7], the increasing trend merits attention in the
management of such patients. Some improvements in
therapy have been promoted; however, successful
management of these infections is often quite problematic.
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Invasive fungal infections, a serious problem among cancer patients, are increasing in incidence, and can
cause morbidity and mortality. Such infections may hinder additional treatment, especially for patients with
leukemia. We report here our experiences in the management of invasive fungal infection in patients with
acute leukemia. A total of 18 patients were enrolled in the study: 12 had microabscesses of the liver and/or
spleen and/or kidneys; four had sinonasal infections; and two had pulmonary infections. Most of the
patients (88.9%) received amphotericin B during treatment for fungal infection. Thirteen patients achieved
complete response without evidence of fungal infection in follow-up. In the study, there were 11 mortalities,
including five patients who died during therapy and six who later died as a result of relapse or refractoriness
of the leukemia. We suggest that many patients may have a good response to antifungal therapy, and that
fungal infection does not have to preclude additional chemotherapy after proper management. The state of
the underlying disease has a strong impact on outcome.
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Nonspecific clinical symptoms and/or signs, equivocal
imaging results, and inadequate specimen sampling have
hampered early diagnosis [8–10]. The toxicity and efficacy
of antifungal agents also hinder appropriate treatment of
the disease [11–14].
In this study, we retrospectively enrolled patients, in
our hospital, with acute leukemia who suffered from
invasive fungal infections. Clinical characteristics, treatment
strategies, and outcomes of these patients were reviewed
and analyzed in the hope of gaining more knowledge
about fungal infections.
MATERIALS AND METHODS
Patients
From January 2000 to August 2005, medical records of acute
leukemia patients treated in the hematology ward of the
Kaohsiung Medical University Hospital were reviewed.
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A total of 18 patients who met the criteria of invasive fungal
infection were enrolled retrospectively. The diagnosis of
invasive fungal infection was made according to the
definition proposed by the Invasive Fungal Infection
Cooperative Group (IFICG) of the European Organization
for Research and Treatment of Cancer (EORTC) [15]. A
proven case was defined as a patient with a comparable
imaging in an immune-compromised state, and a diagnosis
of fungal infection based on biopsy specimens or blood
culture. A probable case was defined as a patient with a
comparable imaging in an immune-compromised state. All
patients received cytotoxic agents according to their state.
Antifungal therapy
Amphotericin B (0.5–1.0 mg/kg) or fluconazole (400 mg/
day) was prescribed empirically for neutropenic patients
who had persistent unexplained fever for 4–6 days after
receiving empiric antibiotics [16]. If patients could not
tolerate the toxicity or had poor response to previous agents,
we switched to other agents for their treatment, such as
voriconazole or caspofungin, which were used at standard
doses. All regimens and doses were adjusted, based on
clinical response, laboratory data, and radiologic findings.
Response
Response to treatment was assessed mainly by clinical
evaluation and serial imaging studies. A complete response
(CR) was defined as total resolution of all clinical symptoms
and signs, the disappearance of fungal lesions in imaging
studies, and negative culture findings.
RESULTS
There was a total of 18 patients in the study, 10 males and
eight females (Table 1). The median age was 38.5 years old
(range, 15–68 years); 14 patients had acute myelogenous
leukemia, whereas the other four patients had acute
lymphoid leukemia. All patients suffered from neutropenic
fever due to marrow suppression from cytotoxic agents
and/or refractory leukemia. Twelve patients had
microabscess of the liver and/or spleen and/or kidneys;
Table 1. Characteristics of patients with fungal infection (n = 18)
Characteristic Number
Gender
Male 10
Female 8
Median age in years (range) 38.5 (15–68)
Diagnosis
AML 14
ALL 4
Site of infection
Microabscess 12
Sinonasal 4
Pulmonary 2
Invasive procedure type
Biopsy 4 sinonasal infections
Liver aspiration 6 microabscess infections
Bronchoscope washing 1 pulmonary infection
Confirmation
Proven 3 (all Aspergillus infections from sinonasal lesions)
Possible 15
Response
CR 13
PR 1
Poor 4
Mortality 11
5 (during therapy) 3 pneumonias, 1 brain hemorrhage, 1 pulmonary hemorrhage
6 (in the follow-up) Relapse and/or refractory of the leukemia
ALL = acute lymphoid leukemia; AML = acute myelogenous leukemia; CR = complete response; PR = partial response.
Invasive fungal Infections in leukemia
Kaohsiung J Med Sci May 2006 • Vol 22 • No 5 219
four had sinonasal infections; and two had pulmonary
infections. All blood cultures for fungal infection revealed
negative findings. Invasive procedures were performed in
11 patients, including biopsies in all four sinonasal cases,
computed tomography or echo-guided aspiration in six
cases of microabscess, and bronchoscopy in one pulmonary
infection. Only three patients, all who had sinonasal
infections, showed positive results and were considered as
proven cases from these procedures.
Although the treatment courses varied, most of the
patients (16/18, 88.9%) had received amphotericin B in the
course of therapy, especially those with sinonasal and
pulmonary infections (Table 2). Only two patients with
microabscess received fluconazole alone because of their
poor general condition. Five of these received more than
one agent. Thirteen patients had CR with no evidence of
fungal infection in follow-up, whereas four patients showed
poor response and one patient had partial response (no. 18,
with improved symptoms and imaging, died from a
pulmonary hemorrhage during therapy). All patients with
CR later received additional chemotherapy without evidence
of recurrent fungal infections, including two patients (nos
4 and 7) who received high-dose chemotherapy plus stem
cell transplant.
There were 11 mortalities in the follow-up. Of these, five
patients died from different causes during antifungal
therapy, including three from pneumonia, one from brain
hemorrhage, and one from pulmonary hemorrhage. Relapse
and/or refractory leukemia caused the other six mortalities
in the follow-up.
Table 2. Treatment courses and outcomes of patients
Patient Age/
no. gender
Diagnosis Treatment Response Outcome
Microabscess
1 34/F AML Amp (2,625 mg) Poor Died, brain hemorrhage during antifungal therapy
2 40/F ALL Amp (2,006 mg) + Poor Died, pneumonia during antifungal therapy
  Flu (400 mg/day)
3 50/M AML Flu (400 mg/day) A CR Died 4 months later, relapse of leukemia
  Amp (586 mg)
4 32/M ALL Flu (800 mg/day) CR Died 8 months later, relapse of leukemia after stem cell transplantation
5 34/M AML Flu (400 mg/day) CR Died 2 months later, refractory of the leukemia
6 63/M AML Amp (1,005 mg) CR Alive (24 months)
7 44/F AML Amp (2,155 mg) A CR Died 10 months later, relapse of the leukemia after
  Flu (400 mg/day)   stem cell transplantation
8 15/F ALL Amp (2,985 mg) + CR Alive (6 months)
  Flu (400 mg/day) + Vori
  + Cas
9 28/F ALL Amp (1,935 mg) + CR Alive (16 months)
  Flu (400 mg/day) + Vori
10 35/F AML Amp (1,455 mg) CR Alive (8 months)
11 63/M AML Amp (865 mg) Poor Died, pneumonia during antifungal therapy
12 34/M AML Amp (1,005 mg) CR Died 4 months later, relapse of the leukemia
Sinonasal infection
13 68/F AML Amp (436 mg) Poor Died, pneumonia during antifungal therapy
14 36/M AML Amp (996 mg) CR Lost to follow-up 2 months later
15 40/F AML Amp (1,006 mg) CR Died 2 months later, refractory of the leukemia
16 37/M AML Amp (1,486 mg) CR Alive (4 months)
Pulmonary infection
17 45/M AML Amp (1,006 mg) CR Alive (26 months)
18 48/M AML Amp (786 mg) PR Died, pulmonary hemorrhage during antifungal therapy
ALL = acute lymphoid leukemia; AML = acute myelogenous leukemia; Amp = amphotericin B; Cas = caspofungin; CR = complete response; Flu =
fluconazole; PR = partial response; Vori = voriconazole.
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DISCUSSION
Invasive fungal infection is a serious problem among
cancer patients, causing considerable morbidity and
mortality [1–7]. This problem is not only confined to Western
countries; Chen et al demonstrated a 7.4% frequency of
hepatosplenic fungal infection in adult acute leukemia
patients in Taiwan [17]. Although there has been some
improvement in the management of fungal infection,
successful therapy of invasive fungal infection still relies
on early recognition of the infection, proper initiation of
antifungal therapy, and improvement of the underlying
neutropenic status [6, 8,11].
Early diagnosis of the fungal infection is often
problematic because persistent fever may be the only
clinical symptom [16–19]. In contrast to our patients with
sinonasal and pulmonary infections, who had obvious
symptoms, identification of intra-abdominal microabscess
might depend on the skills of experienced physicians and
diagnostic aids, such as imaging and microbiologic
data. Although positive results from cytologic evaluation
and/or positive results of culture from sterile body samples
have been the gold standard to confirm fungal infections,
our data showed a low incidence of positive results from
these procedures. This was especially apparent in patients
with microabscess, in whom no positive results were noted
in all six patients who underwent invasive aspiration, even
though multiple nodules were found in the imaging studies.
This failure might be due to the difficulty in identifying the
small lesions for aspiration or in demonstrating the
pseudohyphae or yeast forms from the samples in the
neutropenic phase [4,8,20]. Only three cases of sinonasal
infection from Aspergillus were found from the biopsies,
suggesting the importance of biopsy in this kind of fungal
infection in patients at risk. Thus, novel diagnostic methods
are needed to allow early identification of this type of
infection [21,22].
The use of amphotericin B empirically is a standard
practice in cancer patients with neutropenic fever that
persists for 3–7 days and does not respond to broad-spectrum
antibiotics [16,18–20,23]. Although amphotericin B causes
many complications, including fever, chills, electrolyte
imbalances, and renal failure [13,14], it remains the mainstay
of therapy for systemic fungal infections. With respect to
our study, most of our patients (88.9%) received
amphotericin B therapy, especially patients with Aspergillus
infection and pulmonary infection [22]. Although some
patients had poor response and died during therapy, more
than half of them had good response after a cumulative
dosage of amphotericin B greater than 1,000 mg. However,
optimal dosage depends on individual response to the
drug, such as in case no. 8 who finally achieved CR with a
cumulative dosage of greater than 2,900 mg of amphotericin
B, after failing to respond to initial amphotericin B therapy
(as high as 1,000 mg), fluconazole, voriconazole, and
caspofungin. Even though many agents (including
fluconazole, voriconazole, and caspofungin) had been
prescribed for some of our cases, the efficacy of these agents
against invasive fungal infection has not been well
demonstrated [11,12]. The treatment course seemed effective
in our cases; however, unknown pathogens in most of them
hindered us from finding the optimal agent and dosage for
these patients.
The response to the antifungal therapy seemed adequate,
but the prognosis of patients relies mainly on the state of the
underlying diseases [6]. Among our 11 mortalities, six
patients died as a result of relapse and/or refractoriness of
the leukemia. Four of the other five patients who died
during antifungal therapy suffered from persistent
neutropenia due to refractory leukemia. This result implies
that the underlying state still strongly influences the
outcome. Although the outcome seemed poor, a good
response after adequate antifungal therapy made it possible
for many of our patients to receive additional chemotherapy,
without recurrence of fungal infection, even for stem cell
transplantations. Our data concurred with other reports
showing that fungal infection might not preclude further
chemotherapy or be considered as an absolute
contraindication for stem cell transplantation after
appropriate treatment [17,24].
In summary, we report here our experience in the
management of 18 acute leukemia patients with invasive
fungal infections. Although there were some limitations to
this retrospective work, our study showed that many of our
patients had a good response to therapy, and that fungal
infection might not preclude additional chemotherapy after
proper management. The state of the underlying disease
had a strong impact on the outcome.
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